Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Rheumatology and Therapy|November 20, 2023
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial SpondyloarthritisAndrea Rubbert-Roth, Adriana M Kakehasi, Tsutomu Takeuchi, et al.
Journal of Clinical Medicine|September 29, 2019
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau CohortsRuediger B Mueller, Caroline Hasler, Florian Popp, et al.
The Journal of Rheumatology|March 5, 2013
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposureMark C Genovese, Andrea Rubbert-Roth, Josef S Smolen, et al.
Rheumatology and Therapy|January 20, 2023
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical StudiesPeter C Taylor, Yun-Fei Chen, Janet Pope, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trialsRobert J Moots, Anthony Sebba, William Rigby, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trialMark C Genovese, Roy Fleischmann, Bernard Combe, et al.
The Journal of Rheumatology|July 18, 2008
Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA TrialXavier Le Loët, Dan Nordström, Manuel Rodriguez, et al.
BMJ Open|July 15, 2021
Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritisBenoit Thomas P Gilbert, Céline Lamacchia, Denis Mongin, et al.
Rheumatology (Oxford, England)|May 17, 2022
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapyAndrea Amstad, Eleftherios Papagiannoulis, Almut Scherer, et al.
Medical Microbiology and Immunology|February 14, 2015
Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologicsJens Verheyen, Kseniya Maizus, Eugen Feist, et al.
Pageof 9